Inventiva Sa

Inventiva Sa Current Assets

The Current Assets of Inventiva Sa (IVA) as of Oct 18, 2026 is 266.89 M USD. In the previous year, Current Assets was 112.67 M USD — a change of 136.88% (higher).

Current Assets

266.89 MUSD

YoY

136.88%

Last updated:

Current Assets of Inventiva Sa is 2025 266.89 M USD. Current Assets of Inventiva Sa was 2024 112.67 M USD. It decreases by 136.88% higher compared to the previous year.

The Inventiva Sa Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
66.13 M USD
Jan 1, 2019
54.70 M USD
Jan 1, 2020
135.49 M USD
Jan 1, 2021
117.93 M USD
Jan 1, 2022
110.05 M USD
Jan 1, 2023
36.84 M USD
Jan 1, 2024
112.67 M USD
Jan 1, 2025
266.89 M USD
The Inventiva Sa Current Assets history
YEARCurrent AssetsYoY
266.89 MUSD+136.88%
112.67 MUSD+205.87%
36.84 MUSD-66.53%
110.05 MUSD-6.68%
117.93 MUSD-12.96%
135.49 MUSD+147.71%
54.70 MUSD-17.29%
66.13 MUSD-3.38%
68.45 MUSD+49.12%
45.90 MUSD+46.10%
31.42 MUSD+51.43%
20.75 MUSD+24.63%
16.65 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventiva Sa Stock analysis

What does Inventiva Sa do? Inventiva Sa is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. Inventiva Sa is listed on the stock market with the ticker IVA and ISIN US46124U1079. It went public through an IPO on July 10, 2020. The company has 77 employees and operates within the Health Care sector. Its primary product development includes Lanifibranor, a peroxisome proliferator-activated receptor agonist currently in the NATiV3 Phase 3 clinical trial for treating adult patients with MASH. Additionally, the company is developing Odiparcil for mucopolysaccharidoses and has a pre-clinical program targeting TGF-ß for idiopathic pulmonary fibrosis. Inventiva Sa's website is https://inventivapharma.com. The company operates internationally, with its headquarters located in Daix, France. It is incorporated under French law, though the founding year is not specified in the provided information. The company's research and development efforts are centered on innovative therapeutic approaches for serious medical conditions. Inventiva Sa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventiva Sa stock

Current Assets of Inventiva Sa is 266.89 M USD in 2025.

Current Assets of Inventiva Sa changed from 112.67 M USD to 266.89 M USD, representing a 136.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Inventiva Sa since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Inventiva Sa historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Inventiva Sa

All Key Metrics — Inventiva Sa